United Therapeutics Corporation (UTHR)
- Previous Close
363.55 - Open
362.37 - Bid 361.29 x 100
- Ask 365.56 x 100
- Day's Range
360.32 - 366.08 - 52 Week Range
208.62 - 366.08 - Volume
43,939 - Avg. Volume
538,891 - Market Cap (intraday)
16.166B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
16.68 - EPS (TTM)
21.78 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
357.77
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
www.unither.comRecent News: UTHR
View MorePerformance Overview: UTHR
Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UTHR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UTHR
View MoreValuation Measures
Market Cap
16.17B
Enterprise Value
13.70B
Trailing P/E
16.71
Forward P/E
14.49
PEG Ratio (5yr expected)
1.67
Price/Sales (ttm)
6.84
Price/Book (mrq)
2.84
Enterprise Value/Revenue
5.24
Enterprise Value/EBITDA
9.03
Financial Highlights
Profitability and Income Statement
Profit Margin
40.87%
Return on Assets (ttm)
11.79%
Return on Equity (ttm)
19.25%
Revenue (ttm)
2.62B
Net Income Avi to Common (ttm)
1.07B
Diluted EPS (ttm)
21.78
Balance Sheet and Cash Flow
Total Cash (mrq)
2.97B
Total Debt/Equity (mrq)
8.78%
Levered Free Cash Flow (ttm)
649.9M